More than 173 AI-originated drug programs are in clinical development as of early 2026, with the first potential FDA approval…
AI is reshaping pharmaceutical R&D from target identification through clinical trial optimization, compressing drug discovery timelines and unlocking therapeutic targets…
Owkin and AstraZeneca are expanding their AI collaboration to develop new drug discovery models using federated learning, a technique that…